Over a lifetime horizonAspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower costStudy suggests that using AspyreRx can
-Better Therapeutics Inc., a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and Glooko, Inc., a global leader in chronic condition management, today announced a
Shares of LumiraDx Limited (NASDAQ: LMDX) fell sharply in pre-market trading after the company agreed to sell its point-of-care technology platform to Roche.
LumiraDx shares dipped 19.7% to $0.0517 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today disclosed several initiatives aimed at extending the company's